VOSEVI VS. MAVYRET
Here we look at how Vosevi and Mavyret are alike and different.
Vosevi contains three active drugs: sofosbuvir, velpatasvir, and voxilaprevir. Mavyret contains two active drugs: glecaprevir and pibrentasvir.
Vosevi and Mavyret are both approved to treat chronic (long-lasting) hepatitis C in adults. Mavyret is also approved for use in children ages 12 years and older who weigh at least 99 pounds. Both can be used to treat the six main genotypes (strains) of the hepatitis C virus (HCV).
Vosevi is approved to treat:
- people with HCV genotype 1, 2, 3, 4, 5, or 6 who’ve tried antiviral drugs called nonstructural protein 5A (NS5A) inhibitors
- people with HCV genotype 1a or 3 who’ve tried an antiviral drug called sofosbuvir, taken without an NS5A inhibitor
Mavyret is approved to treat:
- people with HCV genotype 1, 2, 3, 4, 5, or 6 who haven’t had treatment before
- people with HCV genotype 1, 2, 3, 4, 5, or 6 who’ve tried other hepatitis C treatments
- people with HCV genotype 1 who’ve tried antiviral drugs called NS5A inhibitors or NS3/4A protease inhibitors, but not both
Vosevi and Mavyret are both approved for use in:
- people without liver cirrhosis (scarring)
- people with compensated cirrhosis (where the liver is damaged but still able to perform its basis functions)
Drug forms and administration
Vosevi and Mavyret both come as tablets that you take by mouth once daily.
Vosevi is taken for 12 weeks. Mavyret is taken for either 8, 12, or 16 weeks. Your treatment length will depend on what treatment you’ve already had and whether you have cirrhosis.
Side effects and risks
Vosevi and Mavyret have some similar side effects and others that differ. Below are examples of these side effects.
More common side effects
These lists contain examples of more common side effects that can occur with Vosevi, with Mavyret, or with both drugs (when taken individually).
- Can occur with Vosevi:
- feeling weak
- insomnia (trouble sleeping
- Can occur with Mavyret:
- feeling weak
- Can occur with both Vosevi and Mavyret:
Serious side effects
Serious side effects that can occur with both Vosevi and Mavyret include:
- hepatitis B reactivation (when a previous infection becomes active again), which can lead to severe liver damage, liver failure, or death (see “Boxed warnings” below)
- serious allergic reaction, with symptoms that can include trouble breathing and angioedema (swelling under your skin, typically in your eyelids, lips, hands, or feet)
Vosevi and Mavyret both have boxed warnings from the FDA. A boxed warning is the strongest warning the FDA requires.
The warning describes a risk of hepatitis B reactivation after starting treatment with either drug. Hepatitis B reactivation can lead to serious liver damage, liver failure, or death.
Your doctor will test you for hepatitis B before you start taking Vosevi or Mavyret. If you test positive for hepatitis B, you may need to take medication to treat it.
Vosevi and Mavyret have slightly different FDA approved uses, but they’re both used to treat chronic hepatitis C.
These drugs haven’t been directly compared in clinical studies. However, studies have found both Vosevi and Mavyret to be highly effective for treating chronic hepatitis C caused by the six main genotypes. They’re both recommended in current treatment guidelines for hepatitis C.
Your doctor may recommend either drug, depending on your medical history and treatment history.
Vosevi and Mavyret are both brand-name drugs. There are currently no generic forms of either drug. Brand-name medications usually cost more than generics.